{
    "id": "fe07b47d-8835-473f-a233-2c8cddbd1aa0",
    "indications": "hydroxychloroquine sulfate tablets antimalarial antirheumatic indicated : treatment uncomplicated malaria due plasmodium falciparum , plasmodium malariae , plasmodium ovale , plasmodium vivax adult pediatric patients . ( 1.1 ) prophylaxis malaria geographic areas chloroquine resistance reported adult pediatric patients . ( 1.1 ) treatment rheumatoid arthritis adults . ( 1.2 ) treatment systemic lupus erythematosus adults . ( 1.3 ) treatment chronic discoid lupus erythematosus adults . ( 1.4 ) limitations ( 1.1 ) : hydroxychloroquine sulfate tablets recommended : treatment complicated malaria . treatment chloroquine hydroxychloroquine-resistant strains plasmodium species . treatment malaria acquired geographic areas chloroquine resistance occurs plasmodium species identified . prophylaxis malaria geographic areas chloroquine resistance occurs . prevention relapses p. vivax p. ovale active hypnozoite liver stage forms parasites . radical cure p. vivax p. ovale infections , concomitant therapy 8-aminoquinoline necessary .",
    "contraindications": "malaria adult pediatric patients ( 2.2 ) : ● prophylaxis : begin weekly doses 2 weeks prior travel endemic area , continue weekly doses endemic area , continue weekly doses 4 weeks leaving endemic area : - adults : 400 mg week - pediatric patients ≥ 31 kg : 6.5 mg/kg 400 mg , week ● treatment uncomplicated malaria : full prescribing information ( fpi ) complete dosing information . rheumatoid arthritis adults ( 2.3 ) : initial : 400 mg 600 mg daily chronic : 200 mg daily 400 mg daily ( two divided doses ) systemic lupus erythematosus adults ( 2.4 ) : 200 mg daily 400 mg daily ( two divided doses ) chronic discoid lupus erythematosus adults ( 2.5 ) : 200 mg daily 400 mg daily ( two divided doses )",
    "warningsAndPrecautions": "hydroxychloroquine sulfate tablets , usp 200 mg white , capsule shaped film-coated tablets debossed `` ꓲꓲꓲ `` one side plain side . tablets available bottles : 100 tablets - ndc 82619-131-01 500 tablets - ndc 82619-131-02 1000 tablets - ndc 82619-131-03",
    "adverseReactions": "hydroxychloroquine sulfate tablets contraindicated patients known hypersensitivity 4-aminoquinoline compounds .",
    "ingredients": [
        {
            "name": "HYDROXYCHLOROQUINE SULFATE",
            "code": "8Q2869CNVH"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        }
    ],
    "organization": "Creekwood Pharmaceuticals LLC",
    "name": "HYDROXYCHLOROQUINE SULFATE",
    "effectiveTime": "20250503",
    "indications_original": "Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. ( 1.1 ) Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. ( 1.1 ) Treatment of rheumatoid arthritis in adults. ( 1.2 ) Treatment of systemic lupus erythematosus in adults. ( 1.3 ) Treatment of chronic discoid lupus erythematosus in adults. ( 1.4 ) Limitations of Use ( 1.1 ): Hydroxychloroquine sulfate tablets are not recommended for the: Treatment of complicated malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary.",
    "contraindications_original": "Malaria in Adult and Pediatric Patients ( 2.2 ): ●    Prophylaxis: Begin weekly doses 2 weeks prior to travel to the endemic area, continue weekly doses while in the endemic area, and continue the weekly doses for 4 weeks after leaving the endemic area: - Adults: 400 mg once a week - Pediatric patients ≥ 31 kg: 6.5 mg/kg up to 400 mg, once a week ●    Treatment of Uncomplicated Malaria: See Full Prescribing Information (FPI) for complete dosing information. Rheumatoid Arthritis in Adults ( 2.3 ): Initial dosage: 400 mg to 600 mg daily Chronic dosage: 200 mg once daily or 400 mg once daily (or in two divided doses) Systemic Lupus Erythematosus in Adults ( 2.4 ): 200 mg once daily or 400 mg once daily (or in two divided doses) Chronic Discoid Lupus Erythematosus in Adults ( 2.5 ): 200 mg once daily or 400 mg once daily (or in two divided doses)",
    "warningsAndPrecautions_original": "Hydroxychloroquine sulfate tablets, USP 200 mg is white, capsule shaped film-coated tablets debossed with \"ꓲꓲꓲ\" on one side and plain on other side. The tablets are available in bottles of:\n                        \n                           100 tablets - NDC 82619-131-01\n                           500 tablets - NDC 82619-131-02\n                           1000 tablets - NDC 82619-131-03",
    "adverseReactions_original": "Hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds."
}